Efalizumab

Drug Profile

Efalizumab

Alternative Names: Anti-CD11a monoclonal antibody - Genentech/Xoma; HU 1124; Hu1124; Raptiva; Xanelim™

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech
  • Developer Genentech; Merck Serono; XOMA
  • Class Monoclonal antibodies
  • Mechanism of Action CD11a antigen antagonists; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Psoriasis
  • Discontinued Psoriatic arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 11 Jun 2009 Withdrawn for Psoriasis in Canada (SC)
  • 08 Jun 2009 Withdrawn for Psoriasis in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top